PL EN


2011 | 1 | 16-22
Article title

Ocena stężeń wybranych czynników proangiogennych a nowotworzenie w grupie chorych leczonych nerkozastępczo

Content
Title variants
Languages of publication
PL
Abstracts
References
  • Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for endstage renal disease: an international collaborative study. Lancet 1999; 354: 93–99.
  • Książek A, Rutkowski B. Nefrologia. Wyd. 1. Lublin: Wydawnictwo Czelej; 2004.
  • Kasiske BL, Snyder JJ , Gilbertson DT, et al. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4: 905–913.
  • Folkman J. Tumor angiogenesis therapeutic implications. N Engl J Med 1971; 285: 1182–1186.
  • Sato TN, Tozawa Y, Teutsch U, et al. Distinct roles of the receptor tyrosine kinases: Tie-1 and Tie-2 in blood vessel formation. Nature 1995; 376: 70–74.
  • De Palma M, Venneri M, Galli R, et al. Tie-2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and mesenchymal population of pericyte progenitors. Cancer Cell 2005; 8: 211–216.
  • Davis S, Aldrich TH, Jones PF, et al. Isolation of angiopoietin-l, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996; 87: 1161–1169.
  • Huang YQ, Li JJ , Karpatkin S. Identification of a family of alternatively spliced mRNA species of angiopoietin-1. Blood 2000; 95(6): 1993–1999.
  • Kim KT, Choi HH, Steinmetz MO, et al. Oligomerization and multimerization are critical for angiopoietin-1 to bind and phosphorylate Tie2. J Biol Chem 2005; 280: 20126–20131.
  • Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis.Science 1997; 277: 55–60.
  • Yamakawa M, Liu LX, Date T, et al. Hypoxia-inducible factor-l mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors. Circ Res 2003; 93: 664–674.
  • Xu Y, Yu Q. Angiopoietin-1, unlike angiopoietin-2, is incorporated into the extracellular matrix via its linker peptide region. J Biol Chem 2001; 276(37): 34990–34998.
  • Fiedler U, Krissl T, Koidl S, et al. Angiopoietinl and angiopoietin2 share the same binding domains in the Tie-2 receptor involving thc first Ig-like loop and the epidermal growth factor-like repeats. J Biol Chem 2003; 278: 1721–1727.
  • L oughna S, Sato TN. Angiopoietin and Tie signaling pathways in vascular development. Matrix Biol 2001; 20: 319––325.
  • Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis.Cell 1996; 87: 1171–1180.
  • Harfouche R, Hussain SN. Signaling and regulation of endothelial cell survival by angiopoietin-2. Am J Physiol Heart Circ Physiol 2006; 291: 635–645.
  • Yu Q, Stamenkovic I. Angiopoietin-2 is implikated in the regulation of tumor angiogenesis. Am J Pathol 2001; 563––570.
  • Vajkoczy P, Farhadi M, Gaumann A, et al. Microtumor growth initiates angiogenic sprouting with simultaneous expressionof VEGF, VEGF receptor-2, and angiopoietin-2. J Clin Invest 2002; 109: 777–785.
  • Shim WS, Teh M, Bapna A, et al. Angiopoietin l promotes tumor angiogenesis and tumor vessel plasticity of human cervical cancer in mice. Exp Cell Res 2002; 279: 299–309.
  • Stoeltzing O, Ahmad SA, Liu W, et al. Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. Cancer Res 2003; 63: 3370–3377.
  • Cao Y, Sonveaux P, Liu S, et al. Systemic overexpression of angiopoietin-2 promotes tumor microvessel regression and inhibits angiogenesis and tumor growth. Cancer Res 2007; 67: 3835–3844.
  • Giuliano JS Jr, Lahni PM, Bigham MT, et al. Plasma angiopoietin-2 levels increase in children following cardiopulmonary bypass. Intensive Care Med 2008; 34(10): 1851–1857.
  • David S, Kümpers P, Lukasz A, et al. Circulating angiopoietin-2 levels increase with progress of chronic kidney disease Nephrol Dial Transplant 2010; 25(8): 2571–2576..
  • David S, Kümpers P, Hellpap J, et al. Angiopoietin 2 and cardiovascular disease in dialysis and kidney transplantation.Am J Kidney Dis 2009; 53(5): 770–778.
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.desklight-db0950bd-658a-40db-b0b9-c3cfe8c65f8c
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.